Director Matthew Klein of ClearPoint Neuro (CLPT) receives 12,417 shares from RSU vesting

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ClearPoint Neuro director Matthew B. Klein settled a restricted stock unit award into common shares. On the May 19, 2026 vesting date, 12,417 restricted stock units converted into an equal number of ClearPoint Neuro common shares at no cash exercise price. These RSUs were originally granted on May 22, 2025 and were scheduled to vest on the earlier of the first anniversary of the grant or the day immediately before the company’s 2026 annual stockholders’ meeting. Following this routine equity compensation event, Klein directly holds 62,935 shares of ClearPoint Neuro common stock.

Insider Trade Summary

12,417 shares exercised/converted

Mixed 2 txns

Insider Klein Matthew B.

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	12,417	$0.00	--
Exercise	Common Stock	12,417	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 62,935 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs settled: 12,417 units Common shares acquired: 12,417 shares Post-transaction holdings: 62,935 shares +2 more

5 metrics

RSUs settled 12,417 units Restricted stock units converting into common stock on May 19, 2026

Common shares acquired 12,417 shares Shares received upon RSU settlement on May 19, 2026

Post-transaction holdings 62,935 shares Total ClearPoint Neuro common stock held directly after transaction

Exercise price $0.00 per share RSUs converted to common stock with no cash exercise price

RSU grant date May 22, 2025 Grant date for 12,417 restricted stock units

Key Terms

Restricted Stock Units, scheduled vesting date, contingent right, annual meeting of stockholders

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

scheduled vesting date financial

"This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date."

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. common stock."

annual meeting of stockholders financial

"vesting on the earlier of the first anniversary of the grant date, or the day immediately preceding the Company's 2026 annual meeting of stockholders."

Form 4 Insider Transactions: What Each Field Means →

05/21/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klein Matthew B.

(Last)

(First)

(Middle)

C/O CLEARPOINT NEURO, INC

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH

CALIFORNIA

92075

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/19/2026		M		12,417	A	⁽¹⁾	62,935	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	05/19/2026		M			12,417	⁽¹⁾	⁽¹⁾	Common Stock	12,417	⁽¹⁾	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

	/s/ Danilo D'Alessandro, by Power of Attorney for Matthew B. Klein	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ClearPoint Neuro (CLPT) report for Matthew B. Klein?

ClearPoint Neuro reported that director Matthew B. Klein settled 12,417 restricted stock units into 12,417 shares of common stock. The transaction occurred on May 19, 2026 as part of a scheduled equity vesting, with no cash exercise price involved.

How many ClearPoint Neuro (CLPT) shares does Matthew B. Klein hold after this Form 4 transaction?

After the May 19, 2026 transaction, Matthew B. Klein directly holds 62,935 shares of ClearPoint Neuro common stock. This position reflects the addition of 12,417 shares received from the vesting and settlement of his restricted stock units granted in May 2025.

What was the origin and vesting schedule of Matthew B. Klein’s 12,417 RSUs at ClearPoint Neuro (CLPT)?

Klein was granted 12,417 restricted stock units on May 22, 2025. These units were set to vest on the earlier of the first anniversary of the grant date or the day immediately preceding ClearPoint Neuro’s 2026 annual meeting of stockholders, leading to their settlement into common shares.

Did Matthew B. Klein buy or sell ClearPoint Neuro (CLPT) shares in this Form 4 filing?

The Form 4 shows no open-market buys or sells by Matthew B. Klein. Instead, 12,417 restricted stock units were exercised and settled into common shares as scheduled equity compensation, increasing his direct ownership without a reported sale of stock.

What does the Form 4 reveal about the structure of ClearPoint Neuro (CLPT) director compensation?

The Form 4 indicates that part of director compensation is paid in restricted stock units that convert into common shares upon vesting. Klein’s 12,417 RSUs granted in May 2025 vested in May 2026 and were settled one-for-one into ClearPoint Neuro common stock.